Search

Your search keyword '"Bolasco A"' showing total 132 results

Search Constraints

Start Over You searched for: Author "Bolasco A" Remove constraint Author: "Bolasco A" Topic humans Remove constraint Topic: humans
132 results on '"Bolasco A"'

Search Results

1. Dietary Management of Incremental Transition to Dialysis Therapy: Once-Weekly Hemodialysis Combined With Low-Protein Diet

2. Adherence to Gluten-free Diet in a Celiac Pediatric Population Referred to the General Pediatrician After Remission

3. Effects of a Novel Amino Acid Formula on Nutritional and Metabolic Status, Anemia and Myocardial Function in Thrice-Weekly Hemodialysis Patients: Results of a Six-Month Randomized Double-Blind Placebo-Controlled Pilot Study

4. Differences and Effects of Metabolic Fate of Individual Amino Acid Loss in High-Efficiency Hemodialysis and Hemodiafiltration

5. Five-Year Inpatient Management of Teenagers With Anorexia Nervosa: Focus on Nutritional Issues

6. Mucosal and Histologic Healing in children with Inflammatory Bowel Disease treated with anti-Tumor Necrosis Factor-alpha

7. The production of on-line dialysis water for extracorporeal dialysis: proposals for an increased safety upgrade: a viewpoint

8. Could there be Haemodynamic Stress Effects on Pro-Inflammatory CD14+CD16+ Monocytes during Convective-Diffusive Treatments? A Prospective Randomized Controlled Trial

9. Etiology and management of pediatric intestinal failure: Focus on the non-digestive causes

10. Gluten Deprivation: What Nutritional Changes Are Found During the First Year in Newly Diagnosed Coeliac Children?

11. Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission

12. Hemodialysis—Nutritional Flaws in Diagnosis and Prescriptions. Could Amino Acid Losses be the Sharpest 'Sword of Damocles'?

13. Nutritional treatment of advanced CKD: twenty consensus statements

14. Clinical Management of Chronic Kidney Disease Patients in Italy. Results from the IRIDE Study

15. Atrophy, oxidative switching and ultrastructural defects in skeletal muscle of the ataxia telangiectasia mouse model

16. Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients

17. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients

18. Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives

19. Differences in Amino Acid Loss Between High-Efficiency Hemodialysis and Postdilution and Predilution Hemodiafiltration Using High Convection Volume Exchange-A New Metabolic Scenario? A Pilot Study

20. [Infrequent and incremental dialysis: differences and definitions]

21. [Practical procedures to launch a once-weekly-dialysis program integrated into a personalized hypoproteic nutrition (CDDP)]

22. CASP4 gene silencing in epithelial cancer cells leads to impairment of cell migration, cell-matrix adhesion and tissue invasion

23. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study

24. Low-protein diets for chronic kidney disease patients: the Italian experience

25. Vitamin D in patients with chronic kidney disease: a position statement of the Working Group 'Trace Elements and Mineral Metabolism' of the Italian Society of Nephrology

26. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis

27. [The Power of Phosphaturia in the Infrequent Hemodialysis]

28. Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial

29. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial

30. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial

31. Selective MAO-B inhibitors: a lesson from natural products

32. Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents

33. Risk for chronic kidney disease in the general population italian reports for the the world kiney days 2007-2009

34. Clinical benefits of phosphate control in progression of end stage renal disease

35. Keto-analogues and essential aminoacids and other supplements in the conservative management of chronic kidney disease

36. Calcium profiling in hemodiafiltration: a new way to reduce the calcium overload risk without compromising cardiovascular stability

37. Intra-dialytic blood oxygen saturation (SO

38. NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease

39. [Incremental approach to hemodialysis: twice a week, or once weekly hemodialysis combined with low-protein low-phosphorus diet?]

40. Vitamins (A, C and E) and oxidative status of hemodialysis patients treated with HFR and HFR-Supra

41. Predilution haemofiltration—the Second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long‐term cross‐over study

42. Synthesis and Selective Inhibitory Activity Against Human COX-1 of Novel 1-(4-Substituted-thiazol-2-yl)-3,5-di(hetero)aryl-pyrazoline Derivatives

43. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential

44. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial

45. The Evolution of Technological Strategies in the Prevention of Dialysis Water Pollution: Sixteen Years’ Experience

46. Erythropoiesis-stimulating agents: switch from intravenous to subcutaneous administration in hemodialyzed patients

47. Hemodiafiltration with Endogenous Reinfusion with and without Acetate-Free Dialysis Solutions: Effect on ESA Requirement

48. Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors

49. Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors

50. Synthesis, Stereochemical Separation, and Biological Evaluation of Selective Inhibitors of Human MAO-B: 1-(4-Arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines

Catalog

Books, media, physical & digital resources